A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
NCT ID: NCT06043700
Last Updated: 2025-11-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
2000 participants
OBSERVATIONAL
2023-09-12
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Implications of Amyloid Pathology
NCT00900770
Biodistribution of [11C]PIB in Patients With Risk Factors for Alzheimer's Disease
NCT03089827
A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease
NCT01561053
Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers
NCT07041450
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
NCT02918539
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
All Participants
Participants with or without symptoms of AD will be enrolled and observed in this study.
No Intervention
No treatment intervention will be administered.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No Intervention
No treatment intervention will be administered.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
\- Those 50 to 64 years of age must have 1 of the following risk factors confirmed prior to blood sample collection:
* First degree relative with dementia onset before age 75,
* Known before screening to have at least 1 Apolipoprotein E4 (APOE4) allele, or
* Known before screening to have elevated brain amyloid according to previous positron emission tomography (PET), cerebrospinal fluid (CSF), or blood testing
2. Provide written informed consent
3. Willing and able to comply with all aspects of the protocol
4. Willing to be referred to a clinical site if the assessment results meet the criteria
Exclusion Criteria
2. Participation in an interventional clinical trial study at the time of consent
50 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eisai Site #3
Clermont, Florida, United States
Eisai Site #1
Lady Lake, Florida, United States
Eisai Site #2
District Heights, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R2000-G000-008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.